相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2003
已完成
6
75.0%
招募中
1
12.5%
Unknown
1
12.5%
暂无批准数据
- Real-world FLEX Study data show MammaPrint High Risk 2 patients had significantly improved 3-year invasive disease-free survival with anthracycline-containing regimens (100% vs 94.8%, p=0.023). - MammaPrint High Risk 1 patients showed no additional benefit from anthracyclines, with identical 3-year IDFS rates of 95.9% for both chemotherapy regimens. - The NCCN Guidelines now recognize MammaPrint as the only genomic test to personalize anthracycline use in HR+HER2- early-stage breast cancer. - Additional ASCO 2026 data link MammaPrint High Risk 2 tumors to homologous recombination deficiency, providing biological rationale for anthracycline sensitivity.
- Updated NCCN clinical practice guidelines now recognize the 70-gene expression profile MammaPrint, combined with the 80-gene BluePrint assay, as tools to identify HR+/HER2- early-stage breast cancer patients who benefit most from anthracycline-based chemotherapy. - Real-world evidence from the FLEX study of 1,261 patients showed that those with High Risk 2 molecular subtypes achieved 100% three-year invasive disease-free survival with anthracycline therapy versus 89.3% with non-anthracycline regimens. - The guideline update represents a shift toward precision oncology, allowing clinicians to optimize specific drug classes based on tumor biology rather than making binary chemotherapy decisions. - This development enables more tailored treatment approaches, intensifying therapy for patients with H2 subtypes while potentially sparing H1 patients from anthracycline-related toxicities like cardiotoxicity and secondary leukemia.
- The MammaPrint 70-gene assay demonstrated significant predictive utility for chemotherapy benefit in hormone receptor-positive, HER2-negative early-stage breast cancer patients, with the strongest benefit observed in High Risk 2 patients. - Patients with MammaPrint High Risk 2 breast cancer showed maximum absolute reduction benefit of 14.2% with chemotherapy, while Low and Ultralow risk categories showed minimal benefit of 1.7% and less than 1.0% respectively. - Real-world evidence from the FLEX study supports using MammaPrint to guide treatment decisions in older patients aged 70 and above, potentially sparing low-risk patients from unnecessary chemotherapy while identifying those who may benefit despite advanced age. - Multivariate analysis confirmed significant interaction between MammaPrint Index and chemotherapy benefit, with pre- or peri-menopausal status significantly associated with greater chemotherapy benefit.
- New FLEX Study data reveals BluePrint molecular subtyping assay can identify Basal-type tumors among MammaPrint High Risk HR+ HER2- breast cancers that respond better to chemotherapy. - Patients with Basal-type tumors showed higher pathological complete response rates following neoadjuvant chemotherapy compared to those with Luminal B tumors, supporting more personalized treatment approaches. - The findings, to be presented at ESMO Breast Cancer 2025, demonstrate how BluePrint's 80-gene signature provides actionable insights that physicians are using to inform real-world treatment decisions.
